Mnemosyne Pharmaceuticals Lands $250,000 Seed Financing Round

  • Feed Type
  • Date
    11/15/2011
  • Company Name
    Mnemosyne Pharmaceuticals
  • Mailing Address
    Undisclosed Providence, RI 02902
  • Company Description
    The company is a Providence-based drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $250,000
  • Transaction Round
    Seed
  • Proceeds Purposes
    Mnemosyne is currently developing a research platform targeting NMDA receptor function, one of the most impactful signaling mechanisms in the brain. The company is aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders.
  • M&A Terms
  • Venture Investor
    Slater Technology Fund

By posting a comment, you agree to our terms and conditions.